 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| L1-79 / Yamo Pharma
Trial completion: A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder (clinicaltrials.gov) - Jul 30, 2024
P2, N=58, Completed, Sponsor: Yamo Pharmaceuticals LLC
Active, not recruiting --> Completed
- || L1-79 / Yamo Pharma
Trial completion date, Trial primary completion date: A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder (clinicaltrials.gov) - Dec 31, 2023
P2, N=58, Active, not recruiting, Sponsor: Yamo Pharmaceuticals LLC
- || L1-79 / Yamo Pharma
Enrollment closed: A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder (clinicaltrials.gov) - Nov 18, 2023
P2, N=58, Active, not recruiting, Sponsor: Yamo Pharmaceuticals LLC
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | L1-79 / Yamo Pharma
Trial completion date, Trial primary completion date: A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder (clinicaltrials.gov) - Jan 27, 2023
P2, N=50, Recruiting, Sponsor: Yamo Pharmaceuticals LLC
Recruiting --> Active, not recruiting Trial completion date: Mar 2023 --> Feb 2024 | Trial primary completion date: Feb 2023 --> Jan 2024
- || L1-79 / Yamo Pharma
Enrollment open: A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder (clinicaltrials.gov) - Jan 25, 2022
P2, N=50, Recruiting, Sponsor: Yamo Pharmaceuticals LLC
Trial completion date: Mar 2023 --> Feb 2024 | Trial primary completion date: Feb 2023 --> Jan 2024 Not yet recruiting --> Recruiting
- || L1-79 / Yamo Pharma
New P2 trial: A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder (clinicaltrials.gov) - Oct 5, 2021
P2, N=50, Not yet recruiting, Sponsor: Yamo Pharmaceuticals LLC
- | L1-79 / Yamo Pharma
Trial completion, Trial completion date, Trial primary completion date: Safety of L1-79 in Adolescent and Adult Males With Autism (clinicaltrials.gov) - Apr 17, 2018
P2, N=42, Completed, Sponsor: F Peter Halas
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial completion date: Mar 2017 --> Feb 2018 | Trial primary completion date: Jan 2017 --> Dec 2017